Utilization and Prognosis of Cardiac Device Implantation in AL Versus ATTR Amyloidosis
Pacing and Clinical Electrophysiology · 2026-07 · 49 (7) · 954-961
DOI: 10.1111/pace.70180 ↗At a glance
Vergleichsstudie in Pacing and Clinical Electrophysiology, published online on 2026-02-25. Written by Bilal Hussain and 7 co-authors. Institution: Division of Cardiology, University of Cincinnati, Cincinnati, Ohio, USA. Major MEDLINE topics: Pacemaker, Artificial, Defibrillators, Implantable, Immunoglobulin Light-chain Amyloidosis, Amyloid Neuropathies, Familial. Cited 1 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Cardiac amyloidosis can cause congestive heart failure, arrhythmias, and heart blocks, which frequently require cardiac device implantation (CDI). However, the differences between light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis CDI requirements are unknown.
Methods
A retrospective analysis was conducted using the National Inpatient Sample 2017–2020 with respective ICD‐10 codes. Weighted multivariate regression was used to analyze in‐hospital mortality by adjusting for confounders.
Results
Among 1,008,010 patients hospitalized for CDI, 160 patients had underlying AL‐AMD, while 200 patients had underlying ATTR‐AMD. Patients undergoing CDI with underlying ATTR‐AMD had a higher mean age (76.7 vs. 68.4 years, p = 0.001), and a higher male proportion (80% vs. 46.8%, p = 0.005) as compared to those with AL‐AMD. ATTR‐AMD had a higher CDI rate than AL‐AMD (1.4% vs. 8.3%). The predominant device implanted in both AL‐AMD and ATTR‐AMD was a permanent pacemaker (PPM) (0.8% vs. 5.7%). Underlying AL‐AMD was associated with higher in‐hospital mortality in patients undergoing PPM (OR 5.1, CI 1.3–19, p = 0.01), and implantable‐cardioverter defibrillator (ICD) implantation (OR 21.5, CI 4.6–99, p < 0.001). Patients undergoing CDI with underlying AL‐AMD had a higher mean length of stay.
Conclusion
ATTR‐AMD has a higher CDI rate as compared to AL‐AMD. Underlying AL‐AMD is associated with higher in‐hospital mortality in patients undergoing PP and ICD implantation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Cardiology, University of Cincinnati, Cincinnati, Ohio, USA.
- Division of Cardiology, Carle Foundation Hospital, Urbana, Illinois, USA.
- Division of Cardiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
- Division of Internal Medicine, McLaren Healthcare, Flint, Michigan, USA.
- Division of Advanced Heart Failure Transplant Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA.
- Division of Internal Medicine, Weifang Medical University, Weifang, China.
ORCID profiles: Sanchit Duhan, Tarun Dasari
Cite
APA
Hussain, B., Duhan, S., Akhtar, K. H., Seri, A. R., Akrawinthawong, K., Gorthi, J., Keisham, B., & Dasari, T. (2026). Utilization and Prognosis of Cardiac Device Implantation in AL Versus ATTR Amyloidosis. Pacing and Clinical Electrophysiology, 49(7), 954-961. https://doi.org/10.1111/pace.70180
Vancouver
Hussain B, Duhan S, Akhtar KH, Seri AR, Akrawinthawong K, Gorthi J, et al. Utilization and Prognosis of Cardiac Device Implantation in AL Versus ATTR Amyloidosis. Pacing and Clinical Electrophysiology. 2026;49(7):954-961. doi:10.1111/pace.70180
BibTeX
@article{Hussain2026,
author = {Hussain, Bilal and Duhan, Sanchit and Akhtar, Khawaja Hassan and Seri, Amith Reddy and Akrawinthawong, Krittapoom and Gorthi, Janardhana and Keisham, Bijeta and Dasari, Tarun},
title = {Utilization and Prognosis of Cardiac Device Implantation in AL Versus ATTR Amyloidosis},
journal = {Pacing and Clinical Electrophysiology},
year = {2026},
volume = {49},
number = {7},
pages = {954--961},
doi = {10.1111/pace.70180}
}
EUVIMED